Education
About Us
Working with TipRanks
Follow Us
Sartorius Stedim Biotech (FR:DIM)
:DIM
DIM Stock Chart & Stats
€164.60
€3.85(1.94%)
At close: 4:00 PM EST
€164.60
€3.85(1.94%)
Day’s Range― - ―
52-Week Range€148.75 - €224.00
Previous CloseN/A
Volume6.35K
Average Volume (3M)78.09K
Market Cap
€16.02B
Enterprise Value€18.13B
Total Cash (Recent Filing)€426.10M
Total Debt (Recent Filing)€2.75B
Price to Earnings (P/E)108.0
Beta1.35
Next Earnings
Apr 23, 2026EPS Estimate
1.25Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)1.12
Shares Outstanding97,330,410
10 Day Avg. Volume78,938
30 Day Avg. Volume78,094
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€231.57Price Target Upside40.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)5.06
Revenue Forecast (FY)€3.19B
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA large TTM revenue rebound indicates renewed demand for Sartorius's bioprocess products. Given the firm's exposure to biologics, vaccines and single-use tech, a sustained top-line recovery supports capacity utilization, long-term customer relationships, and reinvestment into product lines and service capabilities.
Improving LeverageMaterial reduction in leverage versus 2023 strengthens financial flexibility and reduces refinancing risk. A lower debt/equity ratio improves balance sheet resilience, supporting continued R&D, M&A optionality and capital allocation choices over the medium term as the business pursues growth.
Recurring Consumables & PartnershipsA business model built on single-use consumables, services and long-term pharma partnerships creates recurring, less cyclical revenue. This stickiness supports predictable demand, aftermarket sales and enduring customer lock-in, making top-line durability less dependent on one-time equipment sales.
Bears Say
Weak Cash ConversionSignificant decline in free cash flow and low conversion of earnings into cash undermines internal funding capacity. Over months, weak cash conversion limits ability to self-fund capex, acquisitions or dividends, raising reliance on external financing and increasing execution risk for strategic initiatives.
Compressed MarginsMargins are materially below prior peaks and have shown volatility, signalling persistent pressure on profitability. If structural mix shifts or cost pressures persist, sustained lower margins could limit reinvestment, constrain ROI on new products, and reduce resilience to industry downturns.
High Absolute Debt & Modest ROEDespite improved leverage ratios, large absolute debt and modest ROE suggest capital is not generating strong returns. This combination raises interest burden and sensitivity to rate changes, constraining strategic flexibility and potentially forcing trade-offs between growth investments and balance sheet repair.
Sartorius Stedim Biotech News
DIM FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was €148.75 and its highest was €224.00 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €16.02B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Apr 23, 2026 which is in 44 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Feb 03, 2026. The company reported €1.12 earnings per share for the quarter, missing the consensus estimate of €1.264 by -€0.144.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech pays a Notavailable dividend of €0.69 which represents an annual dividend yield of 0.31%. See more information on Sartorius Stedim Biotech dividends here
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.25.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.12 in its last earnings report, missing expectations of €1.264. Following the earnings report the stock price went up 2.537%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in FR:DIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
DIM Stock 12 Month Forecast
Average Price Target
€231.57
▲(40.69% Upside)
Technical Analysis
Options Prices
Currently, No data available
---